Drugs / Donor TCR α/β-depleted Graft/ATG
last change Apr 2017 re-read 2 minutes ago

Donor TCR α/β-depleted Graft/ATG

Developed for
acute myeloid leukemia · myelodysplastic syndrome
Investigated by
Masonic Cancer Center, University of Minnesota

Trials 1 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01370213 Sep 2011 → Apr 2016 acute myeloid leukemia, myelodysplastic syndrome Masonic Cancer Center, University of Minnesota Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Donor TCR α/β-depleted Graft/ATG ClinicalTrials.gov intervention name — accepted as the source's own label NCT01370213